TW200407174A - Composition - Google Patents
Composition Download PDFInfo
- Publication number
- TW200407174A TW200407174A TW092108404A TW92108404A TW200407174A TW 200407174 A TW200407174 A TW 200407174A TW 092108404 A TW092108404 A TW 092108404A TW 92108404 A TW92108404 A TW 92108404A TW 200407174 A TW200407174 A TW 200407174A
- Authority
- TW
- Taiwan
- Prior art keywords
- dry powder
- item
- patent application
- scope
- pharmaceutical composition
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims description 72
- 239000000843 powder Substances 0.000 claims abstract description 48
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 31
- 239000003814 drug Substances 0.000 claims abstract description 21
- 208000023504 respiratory system disease Diseases 0.000 claims abstract description 7
- 150000001720 carbohydrates Chemical class 0.000 claims description 24
- 235000014633 carbohydrates Nutrition 0.000 claims description 24
- 239000002245 particle Substances 0.000 claims description 23
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 21
- WMWTYOKRWGGJOA-CENSZEJFSA-N fluticasone propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O WMWTYOKRWGGJOA-CENSZEJFSA-N 0.000 claims description 19
- 229960000289 fluticasone propionate Drugs 0.000 claims description 18
- 239000007789 gas Substances 0.000 claims description 18
- GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 claims description 16
- 238000003860 storage Methods 0.000 claims description 16
- 229960004017 salmeterol Drugs 0.000 claims description 14
- 239000002775 capsule Substances 0.000 claims description 9
- 150000001875 compounds Chemical class 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 8
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 7
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 7
- 239000008101 lactose Substances 0.000 claims description 7
- 239000004615 ingredient Substances 0.000 claims description 6
- WOTQVEKSRLZRSX-HYSGBLIFSA-N [(2r,3r,4s,5r,6s)-4,5,6-triacetyloxy-3-[(2s,3r,4s,5r,6r)-3,4,5-triacetyloxy-6-(acetyloxymethyl)oxan-2-yl]oxyoxan-2-yl]methyl acetate Chemical compound CC(=O)OC[C@H]1O[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@@H](OC(C)=O)[C@@H]1O[C@H]1[C@H](OC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@@H](COC(C)=O)O1 WOTQVEKSRLZRSX-HYSGBLIFSA-N 0.000 claims description 5
- WOTQVEKSRLZRSX-UHFFFAOYSA-N beta-D-cellobioside octaacetate Natural products CC(=O)OCC1OC(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(COC(C)=O)O1 WOTQVEKSRLZRSX-UHFFFAOYSA-N 0.000 claims description 5
- 239000010419 fine particle Substances 0.000 claims description 5
- 238000009472 formulation Methods 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 4
- 229930195725 Mannitol Natural products 0.000 claims description 4
- 239000001344 [(2S,3S,4R,5R)-4-acetyloxy-2,5-bis(acetyloxymethyl)-2-[(2R,3R,4S,5R,6R)-3,4,5-triacetyloxy-6-(acetyloxymethyl)oxan-2-yl]oxyoxolan-3-yl] acetate Substances 0.000 claims description 4
- WOTQVEKSRLZRSX-JRFIZLOQSA-N [(2r,3r,4s,5r,6r)-4,5,6-triacetyloxy-3-[(2s,3r,4s,5s,6r)-3,4,5-triacetyloxy-6-(acetyloxymethyl)oxan-2-yl]oxyoxan-2-yl]methyl acetate Chemical compound CC(=O)OC[C@H]1O[C@H](OC(C)=O)[C@H](OC(C)=O)[C@@H](OC(C)=O)[C@@H]1O[C@H]1[C@H](OC(C)=O)[C@@H](OC(C)=O)[C@@H](OC(C)=O)[C@@H](COC(C)=O)O1 WOTQVEKSRLZRSX-JRFIZLOQSA-N 0.000 claims description 4
- 125000000837 carbohydrate group Chemical group 0.000 claims description 4
- 239000000594 mannitol Substances 0.000 claims description 4
- 235000010355 mannitol Nutrition 0.000 claims description 4
- ZIJKGAXBCRWEOL-SAXBRCJISA-N Sucrose octaacetate Chemical compound CC(=O)O[C@H]1[C@H](OC(C)=O)[C@@H](COC(=O)C)O[C@@]1(COC(C)=O)O[C@@H]1[C@H](OC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@@H](COC(C)=O)O1 ZIJKGAXBCRWEOL-SAXBRCJISA-N 0.000 claims description 3
- 150000002016 disaccharides Chemical class 0.000 claims description 3
- -1 hydrazone compound Chemical class 0.000 claims description 3
- 230000002209 hydrophobic effect Effects 0.000 claims description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 3
- 150000002772 monosaccharides Chemical class 0.000 claims description 3
- 229940013883 sucrose octaacetate Drugs 0.000 claims description 3
- 230000001225 therapeutic effect Effects 0.000 claims description 3
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims description 2
- GUBGYTABKSRVRQ-CUHNMECISA-N D-Cellobiose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-CUHNMECISA-N 0.000 claims description 2
- 229930091371 Fructose Natural products 0.000 claims description 2
- 239000005715 Fructose Substances 0.000 claims description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims description 2
- 239000001083 [(2R,3R,4S,5R)-1,2,4,5-tetraacetyloxy-6-oxohexan-3-yl] acetate Substances 0.000 claims description 2
- UAOKXEHOENRFMP-ZJIFWQFVSA-N [(2r,3r,4s,5r)-2,3,4,5-tetraacetyloxy-6-oxohexyl] acetate Chemical compound CC(=O)OC[C@@H](OC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@@H](OC(C)=O)C=O UAOKXEHOENRFMP-ZJIFWQFVSA-N 0.000 claims description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 2
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 claims description 2
- 238000012377 drug delivery Methods 0.000 claims description 2
- 239000008103 glucose Substances 0.000 claims description 2
- 238000007789 sealing Methods 0.000 claims description 2
- 239000011859 microparticle Substances 0.000 claims 3
- RAEOEMDZDMCHJA-UHFFFAOYSA-N 2-[2-[bis(carboxymethyl)amino]ethyl-[2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]ethyl]amino]acetic acid Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CCN(CC(O)=O)CC(O)=O)CC(O)=O RAEOEMDZDMCHJA-UHFFFAOYSA-N 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 238000001647 drug administration Methods 0.000 claims 1
- 229930195712 glutamate Natural products 0.000 claims 1
- 230000009931 harmful effect Effects 0.000 claims 1
- 125000001183 hydrocarbyl group Chemical group 0.000 claims 1
- 150000002483 hydrogen compounds Chemical class 0.000 claims 1
- 239000006187 pill Substances 0.000 claims 1
- 238000004804 winding Methods 0.000 claims 1
- 229940079593 drug Drugs 0.000 abstract description 7
- 239000002260 anti-inflammatory agent Substances 0.000 abstract description 3
- 229940124599 anti-inflammatory drug Drugs 0.000 abstract description 3
- 229940124630 bronchodilator Drugs 0.000 abstract description 3
- 230000003637 steroidlike Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 description 14
- 239000013543 active substance Substances 0.000 description 13
- 238000002156 mixing Methods 0.000 description 6
- WSVLPVUVIUVCRA-RJMJUYIDSA-N (2r,3r,4s,5r,6s)-2-(hydroxymethyl)-6-[(2r,3s,4r,5r)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxane-3,4,5-triol;hydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-RJMJUYIDSA-N 0.000 description 5
- 229960001375 lactose Drugs 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 239000004604 Blowing Agent Substances 0.000 description 4
- 208000006673 asthma Diseases 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000004088 foaming agent Substances 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 229960005018 salmeterol xinafoate Drugs 0.000 description 4
- 229960004793 sucrose Drugs 0.000 description 4
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 229960002714 fluticasone Drugs 0.000 description 3
- MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 229950000339 xinafoate Drugs 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 206010014561 Emphysema Diseases 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 238000012387 aerosolization Methods 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 229940112141 dry powder inhaler Drugs 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 150000002430 hydrocarbons Chemical group 0.000 description 2
- 238000002664 inhalation therapy Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 206010039083 rhinitis Diseases 0.000 description 2
- 239000002689 soil Substances 0.000 description 2
- 238000001694 spray drying Methods 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- UAOKXEHOENRFMP-UHFFFAOYSA-N (2,3,4,5-tetraacetyloxy-6-oxohexyl) acetate Chemical compound CC(=O)OCC(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C=O UAOKXEHOENRFMP-UHFFFAOYSA-N 0.000 description 1
- DKGLSYJXYCJSLA-RJMJUYIDSA-N (2R,3R,4S,5R,6S)-2-(hydroxymethyl)-6-[(2R,3S,4R,5R)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxane-3,4,5-triol hydrochloride Chemical compound Cl.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O DKGLSYJXYCJSLA-RJMJUYIDSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 235000017166 Bambusa arundinacea Nutrition 0.000 description 1
- 235000017491 Bambusa tulda Nutrition 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- UQVZNLINGOJPTL-UHFFFAOYSA-N C(=O)O.C1=CC=CC2=CC=CC=C12 Chemical compound C(=O)O.C1=CC=CC2=CC=CC=C12 UQVZNLINGOJPTL-UHFFFAOYSA-N 0.000 description 1
- 101100296719 Caenorhabditis elegans pde-4 gene Proteins 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 241000544583 Heterococcus <yellow-green algae> Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 244000082204 Phyllostachys viridis Species 0.000 description 1
- 235000015334 Phyllostachys viridis Nutrition 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- NJVBTKVPPOFGAT-BRSBDYLESA-N [(2r,3r,4r,5r)-2,3,4,5,6-pentaacetyloxyhexyl] acetate Chemical compound CC(=O)OC[C@@H](OC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H](OC(C)=O)COC(C)=O NJVBTKVPPOFGAT-BRSBDYLESA-N 0.000 description 1
- 230000004308 accommodation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 229960004977 anhydrous lactose Drugs 0.000 description 1
- 230000001078 anti-cholinergic effect Effects 0.000 description 1
- 239000011425 bamboo Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 239000000168 bronchodilator agent Substances 0.000 description 1
- 150000001719 carbohydrate derivatives Chemical class 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000000975 co-precipitation Methods 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- 235000021551 crystal sugar Nutrition 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- QJMMOFKVXUHETR-UHFFFAOYSA-N formic acid;hydroxylamine Chemical compound ON.OC=O QJMMOFKVXUHETR-UHFFFAOYSA-N 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 238000009490 roller compaction Methods 0.000 description 1
- 229940127100 salmeterol-fluticasone Drugs 0.000 description 1
- 230000035936 sexual power Effects 0.000 description 1
- 239000007962 solid dispersion Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229940098465 tincture Drugs 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pulmonology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Otolaryngology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0208609.8A GB0208609D0 (en) | 2002-04-13 | 2002-04-13 | Compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW200407174A true TW200407174A (en) | 2004-05-16 |
Family
ID=9934856
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW092108404A TW200407174A (en) | 2002-04-13 | 2003-04-11 | Composition |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US20050232998A1 (https=) |
| EP (1) | EP1509199A1 (https=) |
| JP (1) | JP2005529874A (https=) |
| KR (1) | KR20040097348A (https=) |
| CN (1) | CN100362986C (https=) |
| AR (1) | AR039408A1 (https=) |
| AU (1) | AU2003224278A1 (https=) |
| BR (1) | BR0309115A (https=) |
| CA (1) | CA2482249A1 (https=) |
| GB (1) | GB0208609D0 (https=) |
| IL (1) | IL164421A0 (https=) |
| IS (1) | IS7501A (https=) |
| MX (1) | MXPA04010082A (https=) |
| NO (1) | NO20044496L (https=) |
| PL (1) | PL373293A1 (https=) |
| RU (1) | RU2004130438A (https=) |
| TW (1) | TW200407174A (https=) |
| WO (1) | WO2003088944A1 (https=) |
| ZA (1) | ZA200408247B (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003024396A2 (en) | 2001-09-17 | 2003-03-27 | Glaxo Group Limited | Dry powder medicament formulations |
| JP2009513531A (ja) * | 2003-07-11 | 2009-04-02 | グラクソ グループ リミテッド | 糖エステルを含む吸入可能医薬製剤 |
| WO2006086270A1 (en) | 2005-02-10 | 2006-08-17 | Glaxo Group Limited | Processes for making lactose utilizing pre-classification techniques and pharmaceutical formulations formed therefrom |
| GB0605723D0 (en) | 2006-03-23 | 2006-05-03 | 3M Innovative Properties Co | Powder filling processes |
| GB0714134D0 (en) * | 2007-07-19 | 2007-08-29 | Norton Healthcare Ltd | Dry-powder medicament |
| WO2009031011A2 (en) * | 2007-09-05 | 2009-03-12 | Pfizer Limited | Xinafoate salt of n4-(2, 2-difluoro-4h-benz0 [1,4] 0xazin-3-one) -6-yl] -5-fluoro-n2- [3- (methylaminocar bonylmethyleneoxy) phenyl] 2, 4-pyrimidinediamine |
| TR201007251A2 (tr) * | 2010-09-01 | 2012-03-21 | Bi̇lgi̇ç Mahmut | Kalsiyum kanal blokörü formülasyonu. |
| TR201007250A2 (tr) * | 2010-09-01 | 2012-03-21 | Bi̇lgi̇ç Mahmut | Selobioz içeren formülasyon. |
| JOP20120023B1 (ar) | 2011-02-04 | 2022-03-14 | Novartis Ag | صياغات مساحيق جافة من جسيمات تحتوي على واحد أو اثنين من المواد الفعالة لعلاج امراض ممرات الهواء الانسدادية او الالتهابية |
| GB201113662D0 (en) * | 2011-08-08 | 2011-09-21 | Prosonix Ltd | Pharmaceutical compositions |
| EP2819645A2 (en) * | 2012-02-28 | 2015-01-07 | Iceutica Holdings Inc. Bvi | Inhalable pharmaceutical compositions |
| US8765725B2 (en) | 2012-05-08 | 2014-07-01 | Aciex Therapeutics, Inc. | Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof |
| AU2013259872B2 (en) | 2012-05-08 | 2018-06-28 | Nicox Ophthalmics, Inc. | Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof |
| EP2874928B1 (en) | 2012-07-19 | 2016-06-15 | Adamis Pharmaceuticals Corporation | Powder feeding apparatus |
| US9815865B2 (en) | 2013-01-07 | 2017-11-14 | Nicox Ophthalmics, Inc. | Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof |
| EP2991625A1 (en) * | 2013-04-29 | 2016-03-09 | Sanofi SA | Inhalable pharmaceutical compositions and the inhaler devices containing them |
| CN104644618A (zh) * | 2013-11-19 | 2015-05-27 | 上海医药工业研究院 | 一种干粉吸入剂及其制备方法 |
| ES2942297T3 (es) * | 2014-07-31 | 2023-05-31 | Vectura Inc | Formulaciones de polvo seco para inhalación |
| WO2016052897A1 (en) * | 2014-09-30 | 2016-04-07 | Hanmi Pharm. Co., Ltd. | Dry powder for inhalation formulation having improved stability of combined active ingredients |
| KR20160117069A (ko) * | 2015-03-31 | 2016-10-10 | 한미약품 주식회사 | 복합 활성성분의 안정성이 개선된 흡입용 캡슐제 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR8007911A (pt) * | 1979-12-06 | 1981-06-16 | Glaxo Group Ltd | Inalador aperfeicoado |
| SE448277B (sv) * | 1985-04-12 | 1987-02-09 | Draco Ab | Indikeringsanordning vid en doseringsanordning for lekemedel |
| DE3682457D1 (de) * | 1985-07-30 | 1991-12-19 | Glaxo Group Ltd | Geraet zur verabreichung von medikamenten an patienten. |
| US5202309A (en) * | 1989-06-30 | 1993-04-13 | Merck & Co., Inc. | Antibiotic cyclopeptide fermentation product |
| IL95590A (en) * | 1989-09-08 | 1996-06-18 | Glaxo Group Ltd | Medicinal preparations containing Salmetrol and Pluticasone Propionate |
| GB9004781D0 (en) * | 1990-03-02 | 1990-04-25 | Glaxo Group Ltd | Device |
| SE9302777D0 (sv) * | 1993-08-27 | 1993-08-27 | Astra Ab | Process for conditioning substances |
| SE9700135D0 (sv) * | 1997-01-20 | 1997-01-20 | Astra Ab | New formulation |
| DK0994887T3 (da) * | 1997-07-03 | 2003-03-17 | Elan Drug Delivery Ltd | Modificerede glycosider, præparater omfattet deraf og fremgangsmåder til anvendelse deraf |
| US6352722B1 (en) * | 1997-12-23 | 2002-03-05 | Quadrant Holdings Cambridge Limited | Derivatized carbohydrates, compositions comprised thereof and methods of use thereof |
| GB9916316D0 (en) * | 1999-07-12 | 1999-09-15 | Quadrant Holdings Cambridge | Dry powder compositions |
| UA73965C2 (en) * | 1999-12-08 | 2005-10-17 | Theravance Inc | b2 ADRENERGIC RECEPTOR ANTAGONISTS |
| GB0020616D0 (en) * | 2000-08-21 | 2000-10-11 | Quadrant Holdings Cambridge | Particulates |
| AU3664102A (en) * | 2000-12-01 | 2002-06-11 | Battelle Memorial Institute | Method for stabilizing biomolecules in liquid formulations |
| NZ528640A (en) * | 2001-03-30 | 2004-06-25 | Jagotec Ag | Medical aerosol formulations |
| EP1507754A1 (en) * | 2002-05-28 | 2005-02-23 | Theravance, Inc. | Alkoxy aryl beta-2 adrenergic receptor agonists |
-
2002
- 2002-04-13 GB GBGB0208609.8A patent/GB0208609D0/en not_active Ceased
-
2003
- 2003-04-10 CA CA002482249A patent/CA2482249A1/en not_active Abandoned
- 2003-04-10 RU RU2004130438/15A patent/RU2004130438A/ru not_active Application Discontinuation
- 2003-04-10 BR BR0309115-5A patent/BR0309115A/pt not_active IP Right Cessation
- 2003-04-10 KR KR10-2004-7016301A patent/KR20040097348A/ko not_active Withdrawn
- 2003-04-10 MX MXPA04010082A patent/MXPA04010082A/es unknown
- 2003-04-10 US US10/510,968 patent/US20050232998A1/en not_active Abandoned
- 2003-04-10 JP JP2003585696A patent/JP2005529874A/ja active Pending
- 2003-04-10 EP EP03720702A patent/EP1509199A1/en not_active Withdrawn
- 2003-04-10 PL PL03373293A patent/PL373293A1/xx unknown
- 2003-04-10 CN CNB038134608A patent/CN100362986C/zh not_active Expired - Fee Related
- 2003-04-10 WO PCT/GB2003/001595 patent/WO2003088944A1/en not_active Ceased
- 2003-04-10 AU AU2003224278A patent/AU2003224278A1/en not_active Abandoned
- 2003-04-11 TW TW092108404A patent/TW200407174A/zh unknown
- 2003-04-11 AR ARP030101279A patent/AR039408A1/es not_active Application Discontinuation
-
2004
- 2004-10-05 IL IL16442104A patent/IL164421A0/xx unknown
- 2004-10-11 IS IS7501A patent/IS7501A/is unknown
- 2004-10-12 ZA ZA200408247A patent/ZA200408247B/xx unknown
- 2004-10-21 NO NO20044496A patent/NO20044496L/no not_active Application Discontinuation
-
2007
- 2007-11-05 US US11/934,983 patent/US20080060645A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| GB0208609D0 (en) | 2002-05-22 |
| JP2005529874A (ja) | 2005-10-06 |
| US20080060645A1 (en) | 2008-03-13 |
| AU2003224278A1 (en) | 2003-11-03 |
| NO20044496L (no) | 2004-11-15 |
| ZA200408247B (en) | 2006-03-29 |
| CN1658837A (zh) | 2005-08-24 |
| AR039408A1 (es) | 2005-02-16 |
| EP1509199A1 (en) | 2005-03-02 |
| RU2004130438A (ru) | 2005-06-10 |
| CA2482249A1 (en) | 2003-10-30 |
| US20050232998A1 (en) | 2005-10-20 |
| MXPA04010082A (es) | 2004-12-13 |
| BR0309115A (pt) | 2005-02-01 |
| CN100362986C (zh) | 2008-01-23 |
| KR20040097348A (ko) | 2004-11-17 |
| PL373293A1 (en) | 2005-08-22 |
| WO2003088944A1 (en) | 2003-10-30 |
| IS7501A (is) | 2004-10-11 |
| IL164421A0 (en) | 2005-12-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20080060645A1 (en) | Dry Powder Inhalant Composition | |
| US9549936B2 (en) | Method for preparing dry powder for inhalation formulation comprising salmeterol xinafoate, fluticasone propionate and tiotropium bromide | |
| CN107205936B (zh) | 包含至少一种通过喷雾干燥得到的增加制剂稳定性的干粉的组合物 | |
| CA2948553A1 (en) | Combinations of tiotropium bromide, formoterol and budesonide for the treatment of copd | |
| US9987229B2 (en) | Process for preparing a medicament | |
| AU2004285592B2 (en) | Soft steroid compositions for use in dry powder inhalers | |
| CN116077471A (zh) | 一种供吸入用的粉雾剂组合物及其制备方法和应用 | |
| BRPI0614394A2 (pt) | uso de sais de tiotrópio | |
| TR2023002209T2 (tr) | Kuru toz i̇nhalasyon kompozi̇syonlarinin hazirlanmasi i̇çi̇n bi̇r yöntem | |
| MXPA06004984A (en) | Soft steroid compositions for use in dry powder inhalers | |
| TW201618759A (zh) | 具有經改善之組合型活性成分之穩定性的吸入型調配物乾粉末 | |
| HK1232788A1 (en) | Combinations of tiotropium bromide, formoterol and budesonide for the treatment of copd | |
| HK1232787A1 (en) | Combinations of formoterol and budesonide for the treatment of copd |